Somatek

Amuza Inc, based in San Diego, CA, is a leading provider of neuroscience research solutions, offering a wide range of tools and equipment for reliable and efficient scientific discovery. With a focus on behavioral neuroscience, microdialysis, neurotransmitter analysis, and wireless neuroscience, Amuza aims to empower researchers with the right tools to unlock the potential for groundbreaking discoveries. Their precise and innovative products optimize the research process, allowing researchers to produce replicable results and save valuable time in their experiments. As a trusted partner in life science research, Amuza is committed to helping researchers improve human lives through their work. With a team of scientists and experts in the field, Amuza understands the challenges faced by researchers and provides custom-tailored solutions to meet their specific needs. From animal training tools that reduce training time by 90% to high-performance HPLC-ECD systems for accurate neurotransmitter analysis, Amuza's products enable researchers to explore neural circuits, study behavior, and obtain reliable data for their research.Generated from the website

Asteres Inc is a San Diego-based company that specializes in providing products and services for retail pharmacies, health systems, and corporate sites. With a strong focus on convenience and efficiency, Asteres has successfully delivered over 4 million prescriptions worldwide, making them a trusted name in the industry. With their innovative ScriptCenter family, Asteres offers a range of features and benefits that cater to the unique needs of their customers, including specialty university clinics and VA facilities. Committed to excellence, Asteres continues to be a leader in the field, providing reliable solutions and exceptional customer support.Generated from the website

Novomedix LLC is a biotechnology company based in San Diego, CA, specializing in the development of novel small molecule multi-pathway modulators for the treatment of cancer, fibrosis, and inflammatory diseases. With decades of expertise in drug development, the company has established a robust pipeline utilizing their proprietary technology platform, featuring a library of oral small molecule IL-11 inhibitors. The company's lead candidate, NMX1, targets mTOR signaling and IL-11 secretion, aiming to treat tumors while also activating AMPK to protect heart function in triple-negative breast cancer. Novomedix is committed to advancing multiple therapeutic candidates designed to address various fibrotic diseases, liquid tumors, and atopic dermatitis, reflecting its dedication to transforming patient care through innovative treatments. Generated from the website